Dean A Fennell

12PUBLICATIONS
41CO-AUTHORS
Molecular targetsPredictive and prognostic markersMedical infection agents (incl. prions)Innate immunityCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jul 14, 2026
Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer.

|Jan 07, 2026
BAP1-loss in mesothelioma: molecular mechanisms and clinical opportunities.

Jasper H L T van Genugten, Dean A Fennell, Paul Baas

|Aug 07, 2025
Pleural mesothelioma.

Dean A Fennell, Yoshitaka Sekido, Paul Baas

|Jul 21, 2025
Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial.

Dean A Fennell, Kayleigh Hill, Min Zhang

|Aug 21, 2024
A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma.

Min Zhang, Aleksandra Bzura, Essa Y Baitei

|Jul 13, 2024
Targeting DNA Damage Response Deficiency in Thoracic Cancers.

Aleksandra Bzura, Jake B Spicer, Sean Dulloo

Pageof 2

Frequent Collaborators

5 joint publications

Joanna Dzialo

4 joint publications

Hongji Yang

4 joint publications

Edward J Hollox

3 joint publications

Tamihiro Kamata